JP2014514927A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014514927A5 JP2014514927A5 JP2014504319A JP2014504319A JP2014514927A5 JP 2014514927 A5 JP2014514927 A5 JP 2014514927A5 JP 2014504319 A JP2014504319 A JP 2014504319A JP 2014504319 A JP2014504319 A JP 2014504319A JP 2014514927 A5 JP2014514927 A5 JP 2014514927A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- antigen
- specific
- administered
- dendritic cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000001744 T-lymphocyte Anatomy 0.000 claims 19
- 238000000034 method Methods 0.000 claims 15
- 239000000427 antigen Substances 0.000 claims 11
- 102000036639 antigens Human genes 0.000 claims 11
- 108091007433 antigens Proteins 0.000 claims 11
- 210000004443 dendritic cell Anatomy 0.000 claims 9
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 230000000735 allogeneic effect Effects 0.000 claims 5
- 210000000612 antigen-presenting cell Anatomy 0.000 claims 5
- 210000004698 lymphocyte Anatomy 0.000 claims 5
- 210000004027 cell Anatomy 0.000 claims 4
- 239000003446 ligand Substances 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims 4
- 101000831496 Homo sapiens Toll-like receptor 3 Proteins 0.000 claims 3
- 102100024324 Toll-like receptor 3 Human genes 0.000 claims 3
- 238000012258 culturing Methods 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 230000037452 priming Effects 0.000 claims 3
- 102000006306 Antigen Receptors Human genes 0.000 claims 2
- 108010083359 Antigen Receptors Proteins 0.000 claims 2
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 2
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 claims 2
- 102000008070 Interferon-gamma Human genes 0.000 claims 2
- 108010074328 Interferon-gamma Proteins 0.000 claims 2
- 108090000172 Interleukin-15 Proteins 0.000 claims 2
- 108010002350 Interleukin-2 Proteins 0.000 claims 2
- 108010002586 Interleukin-7 Proteins 0.000 claims 2
- 108091036414 Polyinosinic:polycytidylic acid Proteins 0.000 claims 2
- 108091008874 T cell receptors Proteins 0.000 claims 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 2
- 229940124614 TLR 8 agonist Drugs 0.000 claims 2
- 102100039360 Toll-like receptor 4 Human genes 0.000 claims 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 2
- 238000004113 cell culture Methods 0.000 claims 2
- 229960003130 interferon gamma Drugs 0.000 claims 2
- 229940022511 therapeutic cancer vaccine Drugs 0.000 claims 2
- 102000004121 Annexin A5 Human genes 0.000 claims 1
- 108090000672 Annexin A5 Proteins 0.000 claims 1
- 102100027207 CD27 antigen Human genes 0.000 claims 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims 1
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 1
- 101000669402 Homo sapiens Toll-like receptor 7 Proteins 0.000 claims 1
- -1 IL-1β Proteins 0.000 claims 1
- 102000006992 Interferon-alpha Human genes 0.000 claims 1
- 108010047761 Interferon-alpha Proteins 0.000 claims 1
- 102000003996 Interferon-beta Human genes 0.000 claims 1
- 108090000467 Interferon-beta Proteins 0.000 claims 1
- 108090000978 Interleukin-4 Proteins 0.000 claims 1
- 102000043129 MHC class I family Human genes 0.000 claims 1
- 108091054437 MHC class I family Proteins 0.000 claims 1
- 102000043131 MHC class II family Human genes 0.000 claims 1
- 108091054438 MHC class II family Proteins 0.000 claims 1
- 206010070834 Sensitisation Diseases 0.000 claims 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 1
- 102100039390 Toll-like receptor 7 Human genes 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 230000005975 antitumor immune response Effects 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 210000000265 leukocyte Anatomy 0.000 claims 1
- 210000001616 monocyte Anatomy 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 230000008313 sensitization Effects 0.000 claims 1
- 238000010186 staining Methods 0.000 claims 1
- 229940044616 toll-like receptor 7 agonist Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161474904P | 2011-04-13 | 2011-04-13 | |
| US61/474,904 | 2011-04-13 | ||
| PCT/EP2012/056661 WO2012140130A1 (en) | 2011-04-13 | 2012-04-12 | Method for proliferation of antigen-specific t cells |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017049576A Division JP6207783B2 (ja) | 2011-04-13 | 2017-03-15 | 抗原特異的ｔ細胞の増殖のための方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014514927A JP2014514927A (ja) | 2014-06-26 |
| JP2014514927A5 true JP2014514927A5 (enExample) | 2015-05-07 |
Family
ID=45937382
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014504319A Pending JP2014514927A (ja) | 2011-04-13 | 2012-04-12 | 抗原特異的ｔ細胞の増殖のための方法 |
| JP2017049576A Expired - Fee Related JP6207783B2 (ja) | 2011-04-13 | 2017-03-15 | 抗原特異的ｔ細胞の増殖のための方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017049576A Expired - Fee Related JP6207783B2 (ja) | 2011-04-13 | 2017-03-15 | 抗原特異的ｔ細胞の増殖のための方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US9476028B2 (enExample) |
| EP (1) | EP2697367B1 (enExample) |
| JP (2) | JP2014514927A (enExample) |
| KR (1) | KR102028340B1 (enExample) |
| CN (1) | CN103502439B (enExample) |
| WO (1) | WO2012140130A1 (enExample) |
Families Citing this family (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5825966B2 (ja) * | 2011-10-11 | 2015-12-02 | 株式会社日本バイオセラピー研究所 | Ｃｄ５６陽性ｔ細胞増強方法 |
| ES2548229T3 (es) * | 2012-12-18 | 2015-10-15 | Immunicum Ab | Co-diferenciación de monocitos procedentes de donantes alogénicos |
| EP4282419A1 (en) | 2012-12-20 | 2023-11-29 | Purdue Research Foundation | Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics |
| EP3974520A1 (en) | 2013-05-14 | 2022-03-30 | Board of Regents, The University of Texas System | Human application of engineered chimeric antigen receptor (car) t-cells |
| JP6164759B2 (ja) | 2013-11-21 | 2017-07-19 | Ｒｅｐｅｒｔｏｉｒｅ Ｇｅｎｅｓｉｓ株式会社 | Ｔ細胞受容体およびｂ細胞受容体レパトアの解析システムならびにその治療および診断への利用 |
| US20170044496A1 (en) | 2014-04-10 | 2017-02-16 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Enhanced Expansion of Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy |
| AU2015243849B2 (en) * | 2014-04-10 | 2020-12-17 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Transgene genetic tags and methods of use |
| IL296691B2 (en) | 2014-04-25 | 2023-11-01 | 2Seventy Bio Inc | MND promoter chimeric antigen receptors |
| EP3738597A1 (en) * | 2014-04-25 | 2020-11-18 | Bluebird Bio, Inc. | Improved methods for manufacturing adoptive cell therapies |
| CN106793780B (zh) | 2014-06-06 | 2020-05-26 | 蓝鸟生物公司 | 改善的t细胞组合物 |
| MX2017001079A (es) | 2014-07-24 | 2017-09-12 | Bluebird Bio Inc | Receptores de antígeno quiméricos de antígeno de maduración de células b (bcma). |
| MX389823B (es) * | 2014-10-27 | 2025-03-20 | Fred Hutchinson Cancer Center | Composiciones y metodos para reforzar la eficacia de inmunoterapia celular adoptiva. |
| CN104593325A (zh) * | 2014-12-09 | 2015-05-06 | 深圳源正细胞医疗技术有限公司 | 诱导dc成熟并分泌高浓度促炎因子的方法 |
| EP3971210A1 (en) | 2014-12-12 | 2022-03-23 | 2seventy bio, Inc. | Composition for use in the treatment of b cell related conditions in a subject in need thereof comprisine an effector cell comrising a bcma chimeric antigen receptors |
| WO2016179006A1 (en) * | 2015-05-01 | 2016-11-10 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of isolating t cells and t cell receptors having antigenic specificity for a cancer-specific mutation from peripheral blood |
| AU2016259020B2 (en) * | 2015-05-07 | 2021-12-09 | Baylor College Of Medicine | Dendritic cell immunotherapy |
| CN107750271B (zh) * | 2015-05-13 | 2021-12-10 | 泰尔茂比司特公司 | 细胞扩增 |
| JP7269733B2 (ja) * | 2015-06-12 | 2023-05-09 | レンティジェン・テクノロジー・インコーポレイテッド | 操作されたｔ細胞を用いて癌を処置するための方法 |
| WO2017024006A1 (en) * | 2015-08-03 | 2017-02-09 | The Johns Hopkins University | Personalized, allogeneic cell therapy of cancer |
| JP7162530B2 (ja) | 2015-08-07 | 2022-10-28 | シアトル チルドレンズ ホスピタル （ディービーエイ シアトル チルドレンズ リサーチ インスティテュート） | 固形腫瘍を標的とする二重特異性ｃａｒ ｔ細胞 |
| CN108430456B (zh) | 2015-10-22 | 2022-01-18 | 摩登纳特斯有限公司 | 癌症疫苗 |
| WO2017099712A1 (en) | 2015-12-07 | 2017-06-15 | Bluebird Bio, Inc. | Improved t cell compositions |
| ES2964746T3 (es) * | 2015-12-30 | 2024-04-09 | Celgene Corp | Métodos de producción de linfocitos T y linfocitos T producidos mediante el mismo |
| CA3010722A1 (en) * | 2016-01-08 | 2017-07-13 | Prospect CharterCare RWMC, LLC d/b/a Roger Williams Medical Center | Geriatric car-t cells and uses thereof |
| EP3415159B1 (en) * | 2016-02-08 | 2023-12-13 | Mie University | Pretreatment drug for t cell infusion therapy for immune-checkpoint inhibitor-resistant tumor |
| US12144850B2 (en) | 2016-04-08 | 2024-11-19 | Purdue Research Foundation | Methods and compositions for car T cell therapy |
| WO2017179720A1 (ja) | 2016-04-15 | 2017-10-19 | 国立大学法人京都大学 | Ｃｄ８陽性ｔ細胞を誘導する方法 |
| US11723962B2 (en) | 2016-05-04 | 2023-08-15 | Fred Hutchinson Cancer Center | Cell-based neoantigen vaccines and uses thereof |
| US11472856B2 (en) | 2016-06-13 | 2022-10-18 | Torque Therapeutics, Inc. | Methods and compositions for promoting immune cell function |
| EP3475706B1 (en) * | 2016-06-27 | 2021-08-11 | Juno Therapeutics, Inc. | Mhc-e restricted epitopes, binding molecules and related methods and uses |
| CN107779433A (zh) * | 2016-08-30 | 2018-03-09 | 天津市康婷生物工程有限公司 | 便捷的刺激nk细胞增殖和分化的饲养层制备方法 |
| JP2018042481A (ja) * | 2016-09-13 | 2018-03-22 | テラ株式会社 | 抗原特異的ｔ細胞含有組成物及びその製造方法 |
| PL3532607T3 (pl) | 2016-10-26 | 2024-07-01 | Iovance Biotherapeutics, Inc. | Restymulacja kriokonserwowanych limfocytów naciekających guza nowotworowego |
| TWI788307B (zh) | 2016-10-31 | 2023-01-01 | 美商艾歐凡斯生物治療公司 | 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞 |
| KR20240005168A (ko) | 2016-11-04 | 2024-01-11 | 2세븐티 바이오, 인코포레이티드 | 항-bcma car t 세포 조성물 |
| TWI826360B (zh) | 2016-11-17 | 2023-12-21 | 美商艾歐凡斯生物治療公司 | 殘餘腫瘤浸潤性淋巴細胞及製備和使用彼之方法 |
| US20200078400A1 (en) | 2016-12-03 | 2020-03-12 | Juno Therapeutics, Inc. | Methods for determining car-t cells dosing |
| MA46998A (fr) | 2016-12-05 | 2019-10-09 | Juno Therapeutics Inc | Production de cellules modifiées pour une thérapie cellulaire adoptive |
| US11408005B2 (en) | 2016-12-12 | 2022-08-09 | Seattle Children's Hospital | Chimeric transcription factor variants with augmented sensitivity to drug ligand induction of transgene expression in mammalian cells |
| JP7664020B2 (ja) | 2017-01-06 | 2025-04-17 | アイオバンス バイオセラピューティクス，インコーポレイテッド | カリウムチャネルアゴニストによる腫瘍浸潤リンパ球の増殖及びその治療的使用 |
| AU2018219226B2 (en) | 2017-02-07 | 2024-12-19 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents |
| ES3010559T3 (en) | 2017-02-28 | 2025-04-03 | Endocyte Inc | Compositions and methods for car t cell therapy |
| JOP20190224A1 (ar) | 2017-03-29 | 2019-09-26 | Iovance Biotherapeutics Inc | عمليات من أجل إنتاج الخلايا اللمفاوية المرتشحة للأورام واستخداماتها في العلاج المناعي |
| US11254913B1 (en) | 2017-03-29 | 2022-02-22 | Iovance Biotherapeutics, Inc. | Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy |
| US11344578B2 (en) | 2017-04-19 | 2022-05-31 | Board Of Regents, The University Of Texas System | Immune cells expressing engineered antigen receptors |
| CN107502589A (zh) * | 2017-08-04 | 2017-12-22 | 北京世纪劲得生物技术有限公司 | 一种肿瘤浸润淋巴细胞与单个核细胞共培养方法 |
| KR20210032924A (ko) | 2017-09-05 | 2021-03-25 | 토크 테라퓨틱스, 인코포레이티드 | 치료용 단백질 조성물 및 그의 제조 및 사용 방법 |
| KR20200116081A (ko) | 2017-12-01 | 2020-10-08 | 주노 쎄러퓨티크스 인코퍼레이티드 | 유전자 조작된 세포의 투약 및 조절 방법 |
| KR102956273B1 (ko) | 2018-01-08 | 2026-04-24 | 이오반스 바이오테라퓨틱스, 인크. | 종양 항원-특이적 t-세포에 대해 풍부화된 til 생성물의 생성 방법 |
| US11311576B2 (en) | 2018-01-22 | 2022-04-26 | Seattle Children's Hospital | Methods of use for CAR T cells |
| WO2019156795A1 (en) | 2018-02-06 | 2019-08-15 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Fluorescein-specific cars exhibiting optimal t cell function against fl-ple labelled tumors |
| WO2019165121A1 (en) | 2018-02-21 | 2019-08-29 | Board Of Regents, The University Of Texas System | Methods for activation and expansion of natural killer cells and uses therof |
| CA3091674A1 (en) | 2018-02-23 | 2019-08-29 | Endocyte, Inc. | Sequencing method for car t cell therapy |
| WO2019183924A1 (en) * | 2018-03-30 | 2019-10-03 | Syz Cell Therapy Co. | Improved multiple antigen specific cell therapy methods |
| WO2019217753A1 (en) | 2018-05-10 | 2019-11-14 | Iovance Biotherapeutics, Inc. | Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy |
| CN108841792A (zh) * | 2018-06-14 | 2018-11-20 | 浙江大学 | 靶向cd19和ebna1基因修饰的t细胞及其制备方法与应用 |
| TW202039831A (zh) | 2018-11-05 | 2020-11-01 | 美商艾歐凡斯生物治療公司 | 對抗ｐｄ－１抗體呈現難治性之非小細胞肺癌（ｎｓｃｌｃ）病患之治療 |
| CR20210295A (es) | 2018-11-05 | 2021-07-09 | Iovance Biotherapeutics Inc | Procesos para la producción de linfocitos infiltrantes de tumor y usos de estos en inmunoterapia |
| CN109370987A (zh) * | 2018-11-23 | 2019-02-22 | 见多视光(北京)科技有限公司 | 外周血ctl细胞改良的培养方法 |
| JP2022535006A (ja) * | 2019-05-31 | 2022-08-04 | モデルナティエックス インコーポレイテッド | 増殖ｔ細胞アッセイ |
| EP3994245A1 (en) * | 2019-07-05 | 2022-05-11 | Case Western Reserve University | Priming media and methods for stem cell culture and therapy |
| KR20220163940A (ko) | 2020-02-04 | 2022-12-12 | 시애틀 칠드런즈 호스피탈 디/비/에이 시애틀 칠드런즈 리서치 인스티튜트 | 항-디니트로페놀 키메라 항원 수용체 |
| WO2021191870A1 (en) * | 2020-03-27 | 2021-09-30 | Dcprime B.V. | Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy |
| KR20230033647A (ko) | 2020-06-30 | 2023-03-08 | 멘두스 비.브이. | 난소암 백신에서 백혈병 유래 세포의 용도 |
| EP4225330A1 (en) | 2020-10-06 | 2023-08-16 | Iovance Biotherapeutics, Inc. | Treatment of nsclc patients with tumor infiltrating lymphocyte therapies |
| CN113234674B (zh) * | 2021-03-15 | 2023-02-07 | 青岛华赛伯曼医学细胞生物有限公司 | 一种t细胞活化扩增的方法及其应用 |
| WO2022204564A2 (en) | 2021-03-25 | 2022-09-29 | Iovance Biotherapeutics, Inc. | Methods and compositions for t-cell coculture potency assays and use with cell therapy products |
| WO2023201369A1 (en) | 2022-04-15 | 2023-10-19 | Iovance Biotherapeutics, Inc. | Til expansion processes using specific cytokine combinations and/or akti treatment |
| CN115068598A (zh) * | 2022-04-25 | 2022-09-20 | 福建医科大学孟超肝胆医院(福州市传染病医院) | Tlr激动剂以及包含新生抗原的免疫原性组合物在制备药物中的应用 |
| WO2025212473A1 (en) * | 2024-04-01 | 2025-10-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods to identify and selectively expand tumor antigen-specific t cells |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6821778B1 (en) * | 1993-12-01 | 2004-11-23 | The Board Of Trustees Of Leland Stanford Junior University | Methods for using dendritic cells to activate gamma/delta-T cell receptor-positive T cells |
| US5827642A (en) | 1994-08-31 | 1998-10-27 | Fred Hutchinson Cancer Research Center | Rapid expansion method ("REM") for in vitro propagation of T lymphocytes |
| DE69840739D1 (de) * | 1997-10-27 | 2009-05-28 | Merix Bioscience Inc | Methode und Zusammensetzung zur Herstellung von reifen dendritischen Zellen |
| ES2601896T3 (es) * | 2004-11-24 | 2017-02-16 | Fred Hutchinson Cancer Research Center | Procedimientos de uso de la IL-21 en la inmunoterapia adoptiva y la identificación de antígenos tumorales |
| CN102597222B (zh) * | 2009-10-27 | 2015-07-15 | 因缪尼卡姆股份公司 | 用于增殖抗原特异性t细胞的方法 |
-
2012
- 2012-04-12 EP EP12713167.0A patent/EP2697367B1/en active Active
- 2012-04-12 CN CN201280018193.2A patent/CN103502439B/zh not_active Expired - Fee Related
- 2012-04-12 KR KR1020137029248A patent/KR102028340B1/ko not_active Expired - Fee Related
- 2012-04-12 US US14/110,901 patent/US9476028B2/en active Active
- 2012-04-12 JP JP2014504319A patent/JP2014514927A/ja active Pending
- 2012-04-12 WO PCT/EP2012/056661 patent/WO2012140130A1/en not_active Ceased
-
2016
- 2016-10-24 US US15/331,924 patent/US9789174B2/en active Active
-
2017
- 2017-03-15 JP JP2017049576A patent/JP6207783B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2796379A1 (en) | Method for proliferation of antigen-specific t cells | |
| EP2696894B1 (en) | Method for priming of t cells | |
| JP2014511704A5 (enExample) | ||
| KR102028340B1 (ko) | 항원-특이적 t 세포의 증식 방법 | |
| JP6022667B2 (ja) | 炎症性ヒトＴｈ１７細胞の増殖および機能を決定的に調節するＩＣＯＳ | |
| EP1930414B1 (en) | Method for activation treatment of antigen-presenting cell | |
| Hont et al. | The generation and application of antigen-specific T cell therapies for cancer and viral-associated disease | |
| Liu et al. | Induction on differentiation and modulation of bone marrow progenitor of dendritic cell by methionine enkephalin (MENK) | |
| JP6697076B2 (ja) | ウイルス抗原特異的ｔ細胞の濃縮および拡大方法 | |
| KR102121492B1 (ko) | 면역치료를 사용하는 il-12의 유도 | |
| Li et al. | Artificial antigen-presenting cells: the booster for the obtaining of functional adoptive cells | |
| JP2010265327A (ja) | 癌抗原非特異的な標的化ｔ細胞の製造方法及び医薬 | |
| CN113444688B (zh) | 用于抗病毒抗肿瘤的人树突状细胞诱导方法及组合物 | |
| RU2520091C2 (ru) | Способ стимуляции цитотоксического иммунного ответа против клеток опухолевой линии аденокарциномы молочной железы, экспрессирующих специфические антигены, с помощью дендритных клеток, трансфецированных полиэпитопной днк-конструкцией | |
| RU2012116602A (ru) | Способ пролиферации антигенспецифических т-клеток | |
| Foster et al. | Ex-vivo uses and applications of cytokines for adoptive immunotherapy in cancer | |
| US10030227B2 (en) | Canine autologous immunotherapy using dendritic cell induced cancer killing immunocytes | |
| Mohamed et al. | In Vitro Generated Tumor/APC Hybrids Induce Allogeneic Tumor-Killer T Cells | |
| De Bruijn et al. | ANTIGEN BY MURINE DENDRITIC CELLS FOR PRESENTATION TO CYTOTOXIC T LYMPHOCYTES | |
| Hatoya et al. | WS/PP-071-04 Effect of interferon-gamma on immune and clinical responses in dendritic cell-based immunotherapy against cancer K. Sugiura1, K. Mito1, K. Ueda1, T. Hori1, T. Akazawa2, J. Yamate1 | |
| Leen et al. | Multivirus-Specific T Cell Immunotherapy To Prevent Or Treat Infections Of Allogeneic Stem Cell Transplant Recipients | |
| de Pagter et al. | Fast B-And NK-, Reconstitution Early After Unrelated Cord Blood Transplantation Compared To (UN) Related Bone Marrow Transplantation In Children | |
| HK1168869B (en) | Method for proliferation of antigen-specific t cells |